143 related articles for article (PubMed ID: 1974725)
21. Analysis of potential risk factors associated with the development of pancreatitis in phase I patients with AIDS or AIDS-related complex receiving didanosine.
Grasela TH; Walawander CA; Beltangady M; Knupp CA; Martin RR; Dunkle LM; Barbhaiya RH; Pittman KA; Dolin R; Valentine FT
J Infect Dis; 1994 Jun; 169(6):1250-5. PubMed ID: 8195601
[TBL] [Abstract][Full Text] [Related]
22. Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS).
Krown SE; Gold JW; Niedzwiecki D; Bundow D; Flomenberg N; Gansbacher B; Brew BJ
Ann Intern Med; 1990 Jun; 112(11):812-21. PubMed ID: 1971504
[TBL] [Abstract][Full Text] [Related]
23. A pilot study of low-dose zidovudine in human immunodeficiency virus infection.
Collier AC; Bozzette S; Coombs RW; Causey DM; Schoenfeld DA; Spector SA; Pettinelli CB; Davies G; Richman DD; Leedom JM
N Engl J Med; 1990 Oct; 323(15):1015-21. PubMed ID: 1977080
[TBL] [Abstract][Full Text] [Related]
24. Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI.
Reichman RC; Tejani N; Lambert JL; Strussenberg J; Bonnez W; Blumberg B; Epstein L; Dolin R
Antiviral Res; 1993 Apr; 20(4):267-77. PubMed ID: 8097906
[TBL] [Abstract][Full Text] [Related]
25. Zidovudine treatment of patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex: St Stephen's Hospital experience.
Stambuk D; Hawkins D; Gazzard BG
J Infect; 1989 Jan; 18 Suppl 1():41-51. PubMed ID: 2492585
[TBL] [Abstract][Full Text] [Related]
26. In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine.
Yarchoan R; Mitsuya H; Thomas RV; Pluda JM; Hartman NR; Perno CF; Marczyk KS; Allain JP; Johns DG; Broder S
Science; 1989 Jul; 245(4916):412-5. PubMed ID: 2502840
[TBL] [Abstract][Full Text] [Related]
27. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.
Kahn JO; Lagakos SW; Richman DD; Cross A; Pettinelli C; Liou SH; Brown M; Volberding PA; Crumpacker CS; Beall G
N Engl J Med; 1992 Aug; 327(9):581-7. PubMed ID: 1353607
[TBL] [Abstract][Full Text] [Related]
28. A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection.
Nguyen BY; Shay LE; Wyvill KM; Pluda JM; Brawley O; Cohen RB; Whitcup SM; Venzon DJ; Broder S; Yarchoan R
J Infect Dis; 1993 Oct; 168(4):810-7. PubMed ID: 8397267
[TBL] [Abstract][Full Text] [Related]
29. Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trial.
Drusano GL; Yuen GJ; Lambert JS; Seidlin M; Dolin R; Valentine FT
Ann Intern Med; 1992 Apr; 116(7):562-6. PubMed ID: 1347442
[TBL] [Abstract][Full Text] [Related]
30. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
Volberding PA; Lagakos SW; Koch MA; Pettinelli C; Myers MW; Booth DK; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS
N Engl J Med; 1990 Apr; 322(14):941-9. PubMed ID: 1969115
[TBL] [Abstract][Full Text] [Related]
31. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group.
Spruance SL; Pavia AT; Peterson D; Berry A; Pollard R; Patterson TF; Frank I; Remick SC; Thompson M; MacArthur RD; Morey GE; Ramirez-Ronda CH; Bernstein BM; Sweet DE; Crane L; Peterson EA; Pachucki CT; Green SL; Brand J; Rios A; Dunkle LM; Cross A; Brown MJ; Ingraham P; Gugliotti R; Schindzielorz AH; Smaldone L
Ann Intern Med; 1994 Mar; 120(5):360-8. PubMed ID: 7905722
[TBL] [Abstract][Full Text] [Related]
32. Effect of azidothymidine (AZT) on P24 antigen levels in patients with AIDS-related complex and AIDS.
Reddy MM; McKinley G; Englard A; Grieco MH
J Clin Lab Anal; 1989; 3(4):199-201. PubMed ID: 2503599
[TBL] [Abstract][Full Text] [Related]
33. Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex.
Skowron G; Bozzette SA; Lim L; Pettinelli CB; Schaumburg HH; Arezzo J; Fischl MA; Powderly WG; Gocke DJ; Richman DD; Pottage JC; Antoniskis D; McKinley GF; Hyslop NE; Ray G; Simon G; Reed N; LoFaro ML; Uttamchandani RB; Gelb LD; Sperber SJ; Murphy RL; Leedom JM; Grieco MH; Zachary J; Hirsch MS; Spector SA; Bigley J; Soo W; Merigan TC
Ann Intern Med; 1993 Mar; 118(5):321-30. PubMed ID: 8094279
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of continuous-infusion soluble CD4 as a single agent and in combination with oral dideoxyinosine therapy in children with symptomatic human immunodeficiency virus infection.
Husson RN; Chung Y; Mordenti J; Butler KM; Chen S; Duliege AM; Brouwers P; Jarosinski P; Mueller BU; Ammann A
J Pediatr; 1992 Oct; 121(4):627-33. PubMed ID: 1357124
[TBL] [Abstract][Full Text] [Related]
35. Long-term zidovudine treatment of asymptomatic HIV-1-infected subjects.
Mulder JW; de Wolf F; Goudsmit J; Cload PA; Coutinho RA; Fiddian AP; Schellekens PT; van der Noordaa J; Lange JM
Antiviral Res; 1990 Mar; 13(3):127-38. PubMed ID: 1972321
[TBL] [Abstract][Full Text] [Related]
36. Circulating human immunodeficiency virus (HIV) p24 antigen-positive lymphocytes: a flow cytometric measure of HIV infection.
Ohlsson-Wilhelm BM; Cory JM; Kessler HA; Eyster ME; Rapp F; Landay A
J Infect Dis; 1990 Nov; 162(5):1018-24. PubMed ID: 1977803
[TBL] [Abstract][Full Text] [Related]
37. Pilot phase I study using zidovudine in association with a 10-day course of anti-CD4 monoclonal antibody in seven AIDS patients.
Dhiver C; Olive D; Rousseau S; Tamalet C; Lopez M; Galindo JR; Mourens M; Hirn M; Gastaut JA; Mawas C
AIDS; 1989 Dec; 3(12):835-42. PubMed ID: 2576628
[TBL] [Abstract][Full Text] [Related]
38. Effects of therapy with didanosine on hematologic parameters in patients with advanced human immunodeficiency virus disease.
Schacter LP; Rozencweig M; Beltangady M; Allan JD; Canetta R; Cooley TP; Dolin R; Kelley S; Lambert J; Liebman HA
Blood; 1992 Dec; 80(12):2969-76. PubMed ID: 1467512
[TBL] [Abstract][Full Text] [Related]
39. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus.
Richman DD; Grimes JM; Lagakos SW
J Acquir Immune Defic Syndr (1988); 1990; 3(8):743-6. PubMed ID: 2114476
[TBL] [Abstract][Full Text] [Related]
40. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group.
McKinney RE; Maha MA; Connor EM; Feinberg J; Scott GB; Wulfsohn M; McIntosh K; Borkowsky W; Modlin JF; Weintrub P
N Engl J Med; 1991 Apr; 324(15):1018-25. PubMed ID: 1672443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
